{"nctId":"NCT00293033","briefTitle":"Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects","startDateStruct":{"date":"2006-02"},"conditions":["Pain","Cancer"],"count":152,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: BEMA™","Drug: Placebo"]},{"label":"BEMA™ Fentanyl","type":"EXPERIMENTAL","interventionNames":["Drug: BEMA™"]}],"interventions":[{"name":"BEMA™","otherNames":["Onsolis (fentanyl buccal soluble film)"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or non-pregnant and non-lactating female. A female of child-bearing potential is eligible to participate in this study if she is using an acceptable method of birth control.\n* 18 years or older\n* Patient must have pain associated with cancer or cancer treatment.\n* Patient must be on a stable current regimen of oral opioids equivalent to 60 - 1000 mg/day of oral morphine or 50 - 300 µg/hr of transdermal fentanyl (e.g. oxycodone 30 mg, methadone 20 mg, and hydromorphone 7.5 mg).\n* Regularly experiences 1 - 4 breakthrough pain episodes per day that require additional opioids for pain control\n* At least partial relief of breakthrough pain by use of opioid therapy\n* Subject must be able to self-administer the study medication correctly.\n* Subject must be willing and able to complete the electronic diary card with each pain episode.\n* Signed consent must be obtained at screening prior to any procedures being performed.\n\nExclusion Criteria:\n\n* Psychiatric/cognitive or neurological impairment that would limit the subject's ability to understand or complete the diary\n* Cardiopulmonary disease that, in the opinion of the investigator, would significantly increase the risk of respiratory depression\n* Recent history or current evidence of alcohol or other drug substance (licit or illicit) abuse\n* Rapidly escalating pain that the investigator believes may require an increase in the dosage of background pain medication during the study\n* Moderate (Grade 3) to severe (Grade 4) mucositis (Subjects with less than moderate mucositis are permitted and must be instructed to not apply the BEMA disc at a site of inflammation.)\n* Strontium 89 therapy within the previous 6 months\n* Any other therapy prior to the study that the investigator considers could alter pain or the response to pain medication.\n* Use of an investigational drug within 4 weeks preceding this study\n* History of hypersensitivity or intolerance to fentanyl\n* Regularly more than 4 episodes per day\n* Eastern Cooperative Oncology Group (ECOG) performance status of 4 or 5\n* Subject is pregnant, actively trying to become pregnant, breast feeding or not using adequate contraceptive measures","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Summary of Pain Intensity Differences (SPID)","description":"Pain intensity (using an 11-point \\[0 = no pain to 10 = worst pain\\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is\n\n-10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.9","spread":"3.87"},{"groupId":"OG001","value":"38.1","spread":"4.3"}]}]}]},{"type":"SECONDARY","title":"SPID","description":"Pain intensity (using an 11-point \\[0 = no pain to 10 = worst pain\\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"0.30"},{"groupId":"OG001","value":"1.5","spread":"0.36"}]}]}]},{"type":"SECONDARY","title":"SPID","description":"Pain intensity (using an 11-point \\[0 = no pain to 10 = worst pain\\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"0.80"},{"groupId":"OG001","value":"4.9","spread":"0.90"}]}]}]},{"type":"SECONDARY","title":"SPID","description":"Pain intensity (using an 11-point \\[0 = no pain to 10 = worst pain\\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":"1.47"},{"groupId":"OG001","value":"10.4","spread":"1.61"}]}]}]},{"type":"SECONDARY","title":"SPID","description":"Pain intensity (using an 11-point \\[0 = no pain to 10 = worst pain\\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.5","spread":"6.63"},{"groupId":"OG001","value":"70.8","spread":"7.41"}]}]}]},{"type":"SECONDARY","title":"SPID","description":"Pain intensity (using an 11-point \\[0 = no pain to 10 = worst pain\\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"138.0","spread":"9.41"},{"groupId":"OG001","value":"106.0","spread":"10.58"}]}]}]},{"type":"SECONDARY","title":"PID","description":"Pain intensity (using an 11-point \\[0 = no pain to 10 = worst pain\\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.04"},{"groupId":"OG001","value":"0.3","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"PID","description":"Pain intensity (using an 11-point \\[0 = no pain to 10 = worst pain\\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.07"},{"groupId":"OG001","value":"0.7","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"PID","description":"Pain intensity (using an 11-point \\[0 = no pain to 10 = worst pain\\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.09"},{"groupId":"OG001","value":"1.2","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"PID","description":"Pain intensity (using an 11-point \\[0 = no pain to 10 = worst pain\\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"0.11"},{"groupId":"OG001","value":"1.9","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"PID","description":"Pain intensity (using an 11-point \\[0 = no pain to 10 = worst pain\\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"0.13"},{"groupId":"OG001","value":"2.3","spread":"0.17"}]}]}]},{"type":"SECONDARY","title":"PID","description":"Pain intensity (using an 11-point \\[0 = no pain to 10 = worst pain\\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"0.13"},{"groupId":"OG001","value":"2.4","spread":"0.18"}]}]}]},{"type":"SECONDARY","title":"Pain Relief","description":"Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.04"},{"groupId":"OG001","value":"0.4","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Pain Relief","description":"Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.05"},{"groupId":"OG001","value":"0.7","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Pain Relief","description":"Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"0.05"},{"groupId":"OG001","value":"1.0","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Pain Relief","description":"Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.05"},{"groupId":"OG001","value":"1.3","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Pain Relief","description":"Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"0.06"},{"groupId":"OG001","value":"1.5","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Pain Relief","description":"Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"0.06"},{"groupId":"OG001","value":"1.6","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Total Pain Relief","description":"Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest.Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"0.21"},{"groupId":"OG001","value":"1.8","spread":"0.28"}]}]}]},{"type":"SECONDARY","title":"Total Pain Relief","description":"Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"0.40"},{"groupId":"OG001","value":"5.2","spread":"0.54"}]}]}]},{"type":"SECONDARY","title":"Total Pain Relief","description":"Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":"0.62"},{"groupId":"OG001","value":"9.8","spread":"0.82"}]}]}]},{"type":"SECONDARY","title":"Total Pain Relief","description":"Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.1","spread":"1.30"},{"groupId":"OG001","value":"29.5","spread":"1.79"}]}]}]},{"type":"SECONDARY","title":"Total Pain Relief","description":"Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.2","spread":"2.05"},{"groupId":"OG001","value":"52.3","spread":"2.93"}]}]}]},{"type":"SECONDARY","title":"Total Pain Relief","description":"Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.8","spread":"2.84"},{"groupId":"OG001","value":"76.0","spread":"4.16"}]}]}]},{"type":"SECONDARY","title":"Subject Overall Satisfaction With Study Drug","description":"Subjects evaluated their overall satisfaction with study drug at the time rescue medication was consumed or at the 60-minute time point using a 5-point categorical scale (0 = poor, 1 = fair, 2 = good, 3 = very good, and 4 = excellent).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"0.06"},{"groupId":"OG001","value":"1.5","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Percentage of Pain Free Episodes","description":"A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"0.73"},{"groupId":"OG001","value":"1.4","spread":"1.37"}]}]}]},{"type":"SECONDARY","title":"Percentage of Pain Free Episodes","description":"A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"0.72"},{"groupId":"OG001","value":"1.4","spread":"1.35"}]}]}]},{"type":"SECONDARY","title":"Percentage of Pain Free Episodes","description":"A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"1.02"},{"groupId":"OG001","value":"2.0","spread":"1.48"}]}]}]},{"type":"SECONDARY","title":"Percentage of Pain Free Episodes","description":"A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"1.57"},{"groupId":"OG001","value":"4.4","spread":"1.88"}]}]}]},{"type":"SECONDARY","title":"Percentage of Pain Free Episodes","description":"A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":"2.34"},{"groupId":"OG001","value":"6.4","spread":"2.27"}]}]}]},{"type":"SECONDARY","title":"Percentage of Pain Free Episodes","description":"A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":"2.62"},{"groupId":"OG001","value":"9.6","spread":"2.90"}]}]}]},{"type":"SECONDARY","title":"Episodes With at Least 50% Decreases in Pain","description":"Number of episodes where the total pain score has at least a 50% reduction from baseline.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.9","spread":"2.81"},{"groupId":"OG001","value":"14.7","spread":"3.35"}]}]}]},{"type":"SECONDARY","title":"Episodes With at Least 50% Decreases in Pain","description":"Number of episodes where the total pain score has at least a 50% reduction from baseline.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.8","spread":"3.78"},{"groupId":"OG001","value":"24.1","spread":"3.87"}]}]}]},{"type":"SECONDARY","title":"Episodes With at Least 50% Decreases in Pain","description":"Number of episodes where the total pain score has at least a 50% reduction from baseline.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.1","spread":"4.11"},{"groupId":"OG001","value":"30.5","spread":"4.10"}]}]}]},{"type":"SECONDARY","title":"Episodes With at Least 50% Decreases in Pain","description":"Number of episodes where the total pain score has at least a 50% reduction from baseline.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.1","spread":"4.17"},{"groupId":"OG001","value":"34.0","spread":"4.30"}]}]}]},{"type":"SECONDARY","title":"Episodes With at Least 33% Decreases in Pain","description":"Number of episodes where the total pain score has at least a 33% reduction from baseline.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.4","spread":"3.55"},{"groupId":"OG001","value":"21.3","spread":"3.66"}]}]}]},{"type":"SECONDARY","title":"Episodes With at Least 33% Decreases in Pain","description":"Number of episodes where the total pain score has at least a 33% reduction from baseline.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.3","spread":"4.05"},{"groupId":"OG001","value":"38.2","spread":"4.45"}]}]}]},{"type":"SECONDARY","title":"Episodes With at Least 33% Decreases in Pain","description":"Number of episodes where the total pain score has at least a 33% reduction from baseline.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.5","spread":"3.93"},{"groupId":"OG001","value":"46.5","spread":"4.50"}]}]}]},{"type":"SECONDARY","title":"Episodes With at Least 33% Decreases in Pain","description":"Number of episodes where the total pain score has at least a 50% reduction from baseline.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":"3.72"},{"groupId":"OG001","value":"48.2","spread":"4.51"}]}]}]},{"type":"SECONDARY","title":"Episodes With Complete Pain Relief","description":"Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.66"},{"groupId":"OG001","value":"0.7","spread":"0.68"}]}]}]},{"type":"SECONDARY","title":"Episodes With Complete Pain Relief","description":"Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief).Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"0.72"},{"groupId":"OG001","value":"0.7","spread":"0.68"}]}]}]},{"type":"SECONDARY","title":"Episodes With Complete Pain Relief","description":"Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief).Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.83"},{"groupId":"OG001","value":"1.3","spread":"0.94"}]}]}]},{"type":"SECONDARY","title":"Episodes With Complete Pain Relief","description":"Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"1.63"},{"groupId":"OG001","value":"2.6","spread":"1.33"}]}]}]},{"type":"SECONDARY","title":"Episodes With Complete Pain Relief","description":"Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":"2.18"},{"groupId":"OG001","value":"6.4","spread":"2.27"}]}]}]},{"type":"SECONDARY","title":"Episodes With Complete Pain Relief","description":"Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":"2.49"},{"groupId":"OG001","value":"7.2","spread":"2.40"}]}]}]},{"type":"SECONDARY","title":"Rescue Medication Usage","description":"Rescue medication is medication taken if adequate pain relief is not realized within 30 minutes following application of the study drug. Percentage of episodes when rescue medication was used per subject is analyzed.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0","spread":"3.53"},{"groupId":"OG001","value":"44.6","spread":"4.38"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"SPID in Neuropathic Pain Subpopulation","description":"Pain intensity (using an 11-point \\[0 = no pain to 10 = worst pain\\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":"2.93"},{"groupId":"OG001","value":"7.8","spread":"3.20"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"SPID in Neuropathic Pain Subpopulation","description":"Pain intensity (using an 11-point \\[0 = no pain to 10 = worst pain\\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.6","spread":"8.05"},{"groupId":"OG001","value":"31.8","spread":"8.86"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"SPID in Neuropathic Pain Subpopulation","description":"Pain intensity (using an 11-point \\[0 = no pain to 10 = worst pain\\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.0","spread":"14.09"},{"groupId":"OG001","value":"59.7","spread":"15.63"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"SPID in Neuropathic Pain Subpopulation","description":"Pain intensity (using an 11-point \\[0 = no pain to 10 = worst pain\\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"137.8","spread":"20.19"},{"groupId":"OG001","value":"90.9","spread":"22.53"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":151},"commonTop":["Nausea","Vomiting","Somnolence","Dehydration","Dizziness"]}}}